Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Montana Wildhack who wrote (7592)	8/9/2001 4:10:49 PM
From: Joe Krupa	Read Replies (2) \| Respond to of 14101

Hi Wolf, Boy, I have not seen TA discussed on this board in a long long time. In fact, I don't think I have ever gone this long without taking a look that the DMX chart. I pulled it up today for the first time in about a month. Wow, talk about triangles. Connect the November low to the December high, to today's price, and we are still in the pattern. On the daily chart, another very pronounced triangle, or flag pattern, is evident since the low of late June. The flag is certainly approaching an apex both on the weekly and daily chart, and indicates a move very soon. The only negative I see is that the flag on the daily chart would point to a continuation of a down trend. Notice though that on the 6 month, the MACD has been steadily marching up toward the O line. Also notice the Accum/Dist and CMF lines have been heading up for the past 2 months. I see what you mean about the ADX. It's clearly out of room. If nothing else, I think the chart is screaming for a big move one way or the other. Could be exciting times in the very near future, either way you are playing this stock. joe stockcharts.com[l,a]daclyymy[dc][pb50!b200!d20,2][vc60][iUc20!La12,26,9!Ld20!Lh4,3!Lf!Ll14]

To: Montana Wildhack who wrote (7592)	8/15/2001 7:27:09 AM
From: E. T.	Respond to of 14101

Today Globe says in its Vox column one cannot help wonder if the market is well-enough attuned to what seems to be a more and more aggressive stand by the U.S. drug regulator. The number of FDA-imposed delays, reviews or outright product removals is conspicuously high, and rising. Given the recent trends, it is probably a good idea to recalibrate risk-reward equations for biotech firms with products in the review process.